Whitener Capital Management Inc. Has $4.77 Million Position in Johnson & Johnson $JNJ

Whitener Capital Management Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ) by 15.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,705 shares of the company’s stock after purchasing an additional 3,401 shares during the quarter. Johnson & Johnson comprises about 1.1% of Whitener Capital Management Inc.’s portfolio, making the stock its 24th biggest position. Whitener Capital Management Inc.’s holdings in Johnson & Johnson were worth $4,766,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Johnson & Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after buying an additional 3,085,180 shares during the period. Geode Capital Management LLC increased its stake in shares of Johnson & Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after acquiring an additional 1,225,676 shares in the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at $4,877,174,000. Bank of New York Mellon Corp boosted its stake in Johnson & Johnson by 2.7% during the second quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after acquiring an additional 620,039 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Johnson & Johnson by 0.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock worth $2,894,979,000 after purchasing an additional 52,074 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research reports. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a report on Monday, October 20th. Citigroup upped their price target on Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Sanford C. Bernstein increased their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. Argus set a $210.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Finally, HSBC restated a “buy” rating and set a $240.00 price objective on shares of Johnson & Johnson in a report on Wednesday, December 10th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $210.25.

Johnson & Johnson Trading Down 0.1%

Shares of Johnson & Johnson stock opened at $207.54 on Friday. The company has a market capitalization of $500.02 billion, a P/E ratio of 20.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. The stock has a fifty day simple moving average of $199.67 and a 200 day simple moving average of $181.03. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion for the quarter. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s payout ratio is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.